When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Recent Videos in Chronic Lymphocytic Leukemia (CLL) Page 2
Tune in for this comprehensive overview of Chronic Lymphocytic Leukemia (CLL), covering key risk factors, symptoms, and the decision-making process between monitoring and initiating treatment. This episode also…
Once you receive a diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), it is common for the doctor to recommend “active surveillance” where the disease…
